Global Reflux Nephropathy Treatment Market

Reflux Nephropathy Treatment Comprehensive Study by Type (Prophylactic Antibiotics, Antihypertensive Medications, Pain Medications, Others), Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies) Players and Region - Global Market Outlook to 2026

Reflux Nephropathy Treatment Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Reflux Nephropathy Treatment Market Scope
Reflux nephropathy is a kidney disease caused by the backward flow of urine from the bladder into the kidneys. The condition is more common in children and causes persistent urinary tract abnormalities in children, as well as chronic pyelonephritis, high blood pressure, excessive protein loss, obstructive uropathy, and kidney failure in the long run. Reflux nephropathy is thought to occur when the ureters are not properly attached to the bladder, when the valves are malfunctioning, or when a kidney transplant is followed by ureter swelling. Surveillance, medication therapy, and surgical therapy are all used to treat reflux nephropathy, which is divided into five grades based on the severity of the reflux. Prophylactic antibiotics, antihypertensive drugs, pain drugs, urine culture, and a yearly ultrasound of the kidneys are used to treat reflux nephropathy in order to reduce renal scarring and infections. When medical treatment for severe reflux nephropathy fails, surgery is required. In a few circumstances, ureteral re-implantation is used to stop urine from flowing backward. The treatment for reflux nephropathy is determined by the patient's gender and age. The developing research and development by various academic and research institutes, as well as biopharmaceutical firms, leads to the opening of newer treatment options, thereby expanding the global market. A rise in the industry has also been attributed to several government and health-care-related awareness efforts.

The Reflux Nephropathy Treatment market study is segmented by Type (Prophylactic Antibiotics, Antihypertensive Medications, Pain Medications and Others) and major geographies with country level break-up.

Research Analyst at AMA estimates that Asia Pacific Players will contribute to the maximum growth of Global Reflux Nephropathy Treatment market throughout the predicted period.

Abbott (United States), Glaxo SmithKline Pharmaceutical Ltd (United Kingdom), Takeda Pharma (Japan), Cubit Healthcare (India), Cobalt Laboratories Inc (United States), Teva Pharmaceuticals (Israel), Abbot (United States), Lupin Limited (India), Hoffmann-La Roche Ltd. (Switzerland) and Aurobindo Pharma (India) are some of the key players that are part of study coverage.

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
AMA Research has segmented the market of Global Reflux Nephropathy Treatment market by Type, Application and Region.

On the basis of geography, the market of Reflux Nephropathy Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

April 2021 – U.S. Food and Drug Administration approved Farxiga (dapagliflozin) oral tablets to reduce the risk of kidney function decline, kidney failure, cardiovascular death and hospitalization for heart failure in adults with chronic kidney disease who are at risk of disease progression.


Market Trend
  • Increased Research and Development by Various Academic and Research Institutes as Well as Bio-Pharmaceutical Companies

Market Drivers
  • Increased Incidents of Kidney Problems
  • Increased Awareness about Healthcare among People

Opportunities
  • Government Investment in Healthcare Infrastructural Development

Restraints
  • Scarcity of the Drugs for Treatment
  • Threat to the Patients In The Surgical Treatment

Challenges
  • Stringent Regulatory Factors for Approval of Drug


Key Target Audience
Drug Companies, Healthcare Industry, Medical Research Companies, Regulatory Bodies and Others

Report Objectives / Segmentation Covered

By Type
  • Prophylactic Antibiotics
  • Antihypertensive Medications
  • Pain Medications
  • Others
By Distribution Channel
  • Hospitals Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Incidents of Kidney Problems
      • 3.2.2. Increased Awareness about Healthcare among People
    • 3.3. Market Challenges
      • 3.3.1. Stringent Regulatory Factors for Approval of Drug
    • 3.4. Market Trends
      • 3.4.1. Increased Research and Development by Various Academic and Research Institutes as Well as Bio-Pharmaceutical Companies
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Reflux Nephropathy Treatment, by Type, Distribution Channel and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Reflux Nephropathy Treatment (Value)
      • 5.2.1. Global Reflux Nephropathy Treatment by: Type (Value)
        • 5.2.1.1. Prophylactic Antibiotics
        • 5.2.1.2. Antihypertensive Medications
        • 5.2.1.3. Pain Medications
        • 5.2.1.4. Others
      • 5.2.2. Global Reflux Nephropathy Treatment by: Distribution Channel (Value)
        • 5.2.2.1. Hospitals Pharmacies
        • 5.2.2.2. Retail Pharmacies
        • 5.2.2.3. Online Pharmacies
      • 5.2.3. Global Reflux Nephropathy Treatment Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Reflux Nephropathy Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Abbott (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Glaxo SmithKline Pharmaceutical Ltd (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Takeda Pharma (Japan)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Cubit Healthcare (India)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Cobalt Laboratories Inc (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Teva Pharmaceuticals (Israel)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Abbot (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Lupin Limited (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Hoffmann-La Roche Ltd. (Switzerland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Aurobindo Pharma (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Reflux Nephropathy Treatment Sale, by Type, Distribution Channel and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Reflux Nephropathy Treatment (Value)
      • 7.2.1. Global Reflux Nephropathy Treatment by: Type (Value)
        • 7.2.1.1. Prophylactic Antibiotics
        • 7.2.1.2. Antihypertensive Medications
        • 7.2.1.3. Pain Medications
        • 7.2.1.4. Others
      • 7.2.2. Global Reflux Nephropathy Treatment by: Distribution Channel (Value)
        • 7.2.2.1. Hospitals Pharmacies
        • 7.2.2.2. Retail Pharmacies
        • 7.2.2.3. Online Pharmacies
      • 7.2.3. Global Reflux Nephropathy Treatment Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Reflux Nephropathy Treatment: by Type(USD Million)
  • Table 2. Reflux Nephropathy Treatment Prophylactic Antibiotics , by Region USD Million (2015-2020)
  • Table 3. Reflux Nephropathy Treatment Antihypertensive Medications , by Region USD Million (2015-2020)
  • Table 4. Reflux Nephropathy Treatment Pain Medications , by Region USD Million (2015-2020)
  • Table 5. Reflux Nephropathy Treatment Others , by Region USD Million (2015-2020)
  • Table 6. Reflux Nephropathy Treatment: by Distribution Channel(USD Million)
  • Table 7. Reflux Nephropathy Treatment Hospitals Pharmacies , by Region USD Million (2015-2020)
  • Table 8. Reflux Nephropathy Treatment Retail Pharmacies , by Region USD Million (2015-2020)
  • Table 9. Reflux Nephropathy Treatment Online Pharmacies , by Region USD Million (2015-2020)
  • Table 10. South America Reflux Nephropathy Treatment, by Country USD Million (2015-2020)
  • Table 11. South America Reflux Nephropathy Treatment, by Type USD Million (2015-2020)
  • Table 12. South America Reflux Nephropathy Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 13. Brazil Reflux Nephropathy Treatment, by Type USD Million (2015-2020)
  • Table 14. Brazil Reflux Nephropathy Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 15. Argentina Reflux Nephropathy Treatment, by Type USD Million (2015-2020)
  • Table 16. Argentina Reflux Nephropathy Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 17. Rest of South America Reflux Nephropathy Treatment, by Type USD Million (2015-2020)
  • Table 18. Rest of South America Reflux Nephropathy Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 19. Asia Pacific Reflux Nephropathy Treatment, by Country USD Million (2015-2020)
  • Table 20. Asia Pacific Reflux Nephropathy Treatment, by Type USD Million (2015-2020)
  • Table 21. Asia Pacific Reflux Nephropathy Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 22. China Reflux Nephropathy Treatment, by Type USD Million (2015-2020)
  • Table 23. China Reflux Nephropathy Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 24. Japan Reflux Nephropathy Treatment, by Type USD Million (2015-2020)
  • Table 25. Japan Reflux Nephropathy Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 26. India Reflux Nephropathy Treatment, by Type USD Million (2015-2020)
  • Table 27. India Reflux Nephropathy Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 28. South Korea Reflux Nephropathy Treatment, by Type USD Million (2015-2020)
  • Table 29. South Korea Reflux Nephropathy Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 30. Taiwan Reflux Nephropathy Treatment, by Type USD Million (2015-2020)
  • Table 31. Taiwan Reflux Nephropathy Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 32. Australia Reflux Nephropathy Treatment, by Type USD Million (2015-2020)
  • Table 33. Australia Reflux Nephropathy Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 34. Rest of Asia-Pacific Reflux Nephropathy Treatment, by Type USD Million (2015-2020)
  • Table 35. Rest of Asia-Pacific Reflux Nephropathy Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 36. Europe Reflux Nephropathy Treatment, by Country USD Million (2015-2020)
  • Table 37. Europe Reflux Nephropathy Treatment, by Type USD Million (2015-2020)
  • Table 38. Europe Reflux Nephropathy Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 39. Germany Reflux Nephropathy Treatment, by Type USD Million (2015-2020)
  • Table 40. Germany Reflux Nephropathy Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 41. France Reflux Nephropathy Treatment, by Type USD Million (2015-2020)
  • Table 42. France Reflux Nephropathy Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 43. Italy Reflux Nephropathy Treatment, by Type USD Million (2015-2020)
  • Table 44. Italy Reflux Nephropathy Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 45. United Kingdom Reflux Nephropathy Treatment, by Type USD Million (2015-2020)
  • Table 46. United Kingdom Reflux Nephropathy Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 47. Netherlands Reflux Nephropathy Treatment, by Type USD Million (2015-2020)
  • Table 48. Netherlands Reflux Nephropathy Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 49. Rest of Europe Reflux Nephropathy Treatment, by Type USD Million (2015-2020)
  • Table 50. Rest of Europe Reflux Nephropathy Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 51. MEA Reflux Nephropathy Treatment, by Country USD Million (2015-2020)
  • Table 52. MEA Reflux Nephropathy Treatment, by Type USD Million (2015-2020)
  • Table 53. MEA Reflux Nephropathy Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 54. Middle East Reflux Nephropathy Treatment, by Type USD Million (2015-2020)
  • Table 55. Middle East Reflux Nephropathy Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 56. Africa Reflux Nephropathy Treatment, by Type USD Million (2015-2020)
  • Table 57. Africa Reflux Nephropathy Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 58. North America Reflux Nephropathy Treatment, by Country USD Million (2015-2020)
  • Table 59. North America Reflux Nephropathy Treatment, by Type USD Million (2015-2020)
  • Table 60. North America Reflux Nephropathy Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 61. United States Reflux Nephropathy Treatment, by Type USD Million (2015-2020)
  • Table 62. United States Reflux Nephropathy Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 63. Canada Reflux Nephropathy Treatment, by Type USD Million (2015-2020)
  • Table 64. Canada Reflux Nephropathy Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 65. Mexico Reflux Nephropathy Treatment, by Type USD Million (2015-2020)
  • Table 66. Mexico Reflux Nephropathy Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 67. Company Basic Information, Sales Area and Its Competitors
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Reflux Nephropathy Treatment: by Type(USD Million)
  • Table 78. Reflux Nephropathy Treatment Prophylactic Antibiotics , by Region USD Million (2021-2026)
  • Table 79. Reflux Nephropathy Treatment Antihypertensive Medications , by Region USD Million (2021-2026)
  • Table 80. Reflux Nephropathy Treatment Pain Medications , by Region USD Million (2021-2026)
  • Table 81. Reflux Nephropathy Treatment Others , by Region USD Million (2021-2026)
  • Table 82. Reflux Nephropathy Treatment: by Distribution Channel(USD Million)
  • Table 83. Reflux Nephropathy Treatment Hospitals Pharmacies , by Region USD Million (2021-2026)
  • Table 84. Reflux Nephropathy Treatment Retail Pharmacies , by Region USD Million (2021-2026)
  • Table 85. Reflux Nephropathy Treatment Online Pharmacies , by Region USD Million (2021-2026)
  • Table 86. South America Reflux Nephropathy Treatment, by Country USD Million (2021-2026)
  • Table 87. South America Reflux Nephropathy Treatment, by Type USD Million (2021-2026)
  • Table 88. South America Reflux Nephropathy Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 89. Brazil Reflux Nephropathy Treatment, by Type USD Million (2021-2026)
  • Table 90. Brazil Reflux Nephropathy Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 91. Argentina Reflux Nephropathy Treatment, by Type USD Million (2021-2026)
  • Table 92. Argentina Reflux Nephropathy Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 93. Rest of South America Reflux Nephropathy Treatment, by Type USD Million (2021-2026)
  • Table 94. Rest of South America Reflux Nephropathy Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 95. Asia Pacific Reflux Nephropathy Treatment, by Country USD Million (2021-2026)
  • Table 96. Asia Pacific Reflux Nephropathy Treatment, by Type USD Million (2021-2026)
  • Table 97. Asia Pacific Reflux Nephropathy Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 98. China Reflux Nephropathy Treatment, by Type USD Million (2021-2026)
  • Table 99. China Reflux Nephropathy Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 100. Japan Reflux Nephropathy Treatment, by Type USD Million (2021-2026)
  • Table 101. Japan Reflux Nephropathy Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 102. India Reflux Nephropathy Treatment, by Type USD Million (2021-2026)
  • Table 103. India Reflux Nephropathy Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 104. South Korea Reflux Nephropathy Treatment, by Type USD Million (2021-2026)
  • Table 105. South Korea Reflux Nephropathy Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 106. Taiwan Reflux Nephropathy Treatment, by Type USD Million (2021-2026)
  • Table 107. Taiwan Reflux Nephropathy Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 108. Australia Reflux Nephropathy Treatment, by Type USD Million (2021-2026)
  • Table 109. Australia Reflux Nephropathy Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 110. Rest of Asia-Pacific Reflux Nephropathy Treatment, by Type USD Million (2021-2026)
  • Table 111. Rest of Asia-Pacific Reflux Nephropathy Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 112. Europe Reflux Nephropathy Treatment, by Country USD Million (2021-2026)
  • Table 113. Europe Reflux Nephropathy Treatment, by Type USD Million (2021-2026)
  • Table 114. Europe Reflux Nephropathy Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 115. Germany Reflux Nephropathy Treatment, by Type USD Million (2021-2026)
  • Table 116. Germany Reflux Nephropathy Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 117. France Reflux Nephropathy Treatment, by Type USD Million (2021-2026)
  • Table 118. France Reflux Nephropathy Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 119. Italy Reflux Nephropathy Treatment, by Type USD Million (2021-2026)
  • Table 120. Italy Reflux Nephropathy Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 121. United Kingdom Reflux Nephropathy Treatment, by Type USD Million (2021-2026)
  • Table 122. United Kingdom Reflux Nephropathy Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 123. Netherlands Reflux Nephropathy Treatment, by Type USD Million (2021-2026)
  • Table 124. Netherlands Reflux Nephropathy Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 125. Rest of Europe Reflux Nephropathy Treatment, by Type USD Million (2021-2026)
  • Table 126. Rest of Europe Reflux Nephropathy Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 127. MEA Reflux Nephropathy Treatment, by Country USD Million (2021-2026)
  • Table 128. MEA Reflux Nephropathy Treatment, by Type USD Million (2021-2026)
  • Table 129. MEA Reflux Nephropathy Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 130. Middle East Reflux Nephropathy Treatment, by Type USD Million (2021-2026)
  • Table 131. Middle East Reflux Nephropathy Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 132. Africa Reflux Nephropathy Treatment, by Type USD Million (2021-2026)
  • Table 133. Africa Reflux Nephropathy Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 134. North America Reflux Nephropathy Treatment, by Country USD Million (2021-2026)
  • Table 135. North America Reflux Nephropathy Treatment, by Type USD Million (2021-2026)
  • Table 136. North America Reflux Nephropathy Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 137. United States Reflux Nephropathy Treatment, by Type USD Million (2021-2026)
  • Table 138. United States Reflux Nephropathy Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 139. Canada Reflux Nephropathy Treatment, by Type USD Million (2021-2026)
  • Table 140. Canada Reflux Nephropathy Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 141. Mexico Reflux Nephropathy Treatment, by Type USD Million (2021-2026)
  • Table 142. Mexico Reflux Nephropathy Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 143. Research Programs/Design for This Report
  • Table 144. Key Data Information from Secondary Sources
  • Table 145. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Reflux Nephropathy Treatment: by Type USD Million (2015-2020)
  • Figure 5. Global Reflux Nephropathy Treatment: by Distribution Channel USD Million (2015-2020)
  • Figure 6. South America Reflux Nephropathy Treatment Share (%), by Country
  • Figure 7. Asia Pacific Reflux Nephropathy Treatment Share (%), by Country
  • Figure 8. Europe Reflux Nephropathy Treatment Share (%), by Country
  • Figure 9. MEA Reflux Nephropathy Treatment Share (%), by Country
  • Figure 10. North America Reflux Nephropathy Treatment Share (%), by Country
  • Figure 11. Global Reflux Nephropathy Treatment share by Players 2020 (%)
  • Figure 12. Global Reflux Nephropathy Treatment share by Players (Top 3) 2020(%)
  • Figure 13. Global Reflux Nephropathy Treatment share by Players (Top 5) 2020(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Abbott (United States) Revenue, Net Income and Gross profit
  • Figure 16. Abbott (United States) Revenue: by Geography 2020
  • Figure 17. Glaxo SmithKline Pharmaceutical Ltd (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 18. Glaxo SmithKline Pharmaceutical Ltd (United Kingdom) Revenue: by Geography 2020
  • Figure 19. Takeda Pharma (Japan) Revenue, Net Income and Gross profit
  • Figure 20. Takeda Pharma (Japan) Revenue: by Geography 2020
  • Figure 21. Cubit Healthcare (India) Revenue, Net Income and Gross profit
  • Figure 22. Cubit Healthcare (India) Revenue: by Geography 2020
  • Figure 23. Cobalt Laboratories Inc (United States) Revenue, Net Income and Gross profit
  • Figure 24. Cobalt Laboratories Inc (United States) Revenue: by Geography 2020
  • Figure 25. Teva Pharmaceuticals (Israel) Revenue, Net Income and Gross profit
  • Figure 26. Teva Pharmaceuticals (Israel) Revenue: by Geography 2020
  • Figure 27. Abbot (United States) Revenue, Net Income and Gross profit
  • Figure 28. Abbot (United States) Revenue: by Geography 2020
  • Figure 29. Lupin Limited (India) Revenue, Net Income and Gross profit
  • Figure 30. Lupin Limited (India) Revenue: by Geography 2020
  • Figure 31. Hoffmann-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 32. Hoffmann-La Roche Ltd. (Switzerland) Revenue: by Geography 2020
  • Figure 33. Aurobindo Pharma (India) Revenue, Net Income and Gross profit
  • Figure 34. Aurobindo Pharma (India) Revenue: by Geography 2020
  • Figure 35. Global Reflux Nephropathy Treatment: by Type USD Million (2021-2026)
  • Figure 36. Global Reflux Nephropathy Treatment: by Distribution Channel USD Million (2021-2026)
  • Figure 37. South America Reflux Nephropathy Treatment Share (%), by Country
  • Figure 38. Asia Pacific Reflux Nephropathy Treatment Share (%), by Country
  • Figure 39. Europe Reflux Nephropathy Treatment Share (%), by Country
  • Figure 40. MEA Reflux Nephropathy Treatment Share (%), by Country
  • Figure 41. North America Reflux Nephropathy Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Abbott (United States)
  • Glaxo SmithKline Pharmaceutical Ltd (United Kingdom)
  • Takeda Pharma (Japan)
  • Cubit Healthcare (India)
  • Cobalt Laboratories Inc (United States)
  • Teva Pharmaceuticals (Israel)
  • Abbot (United States)
  • Lupin Limited (India)
  • Hoffmann-La Roche Ltd. (Switzerland)
  • Aurobindo Pharma (India)
Select User Access Type

Key Highlights of Report


May 2021 246 Pages 50 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Reflux Nephropathy Treatment Market Quantitative research analysis
Global Reflux Nephropathy Treatment Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a study that suits your business objectives.
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2026.

Know More About Global Reflux Nephropathy Treatment Market Report?

Have a Query? Click Here

Other Related Reports

Reperfusion Injury Comprehensive Study by Application (Heart Injury, Kidney Injury, Intestine Injury, Others), Treatment Type (Therapeutic Hypothermia, Cyclosporin, Stem Cell Therapy, Hydrogen Sulfid...
$ 3450
Cartilage Regeneration Technology Comprehensive Study by Application (Hyaline Cartilage, Fibrocartilage), Treatment (Cell-based (Chondrocyte Transplantation, Stem Cells, Growth Factors), Non-cell-bas...
$ 3650
Wolfram Syndrome Treatment  Comprehensive Study by Type (WFS1 gene (Type 1), WFS2 gene (Type 2)), Application (Retail Pharmacies, E-commerce, Hospital Pharmacies), Treatment (Gene Therapy, Regenerati...
$ 3650
Buerger’s Disease Diagnosis Comprehensive Study by Type (Blood Tests, The Allen’s Test, Angiogram (CT Scan, MRI Scan, X-Ray, Others), Tissue Biopsy, Others), Treatment (Smoking Cessation, Other Treat...
$ 3750
Raynaud’s Phenomenon Management Comprehensive Study by Test (Antinuclear Antibodies Test, Erythrocyte Sedimentation Rate Test, C-reactive Protein Test, Others), Treatment Type (Medication (Calcium Ch...
$ 3450
Cervical Spondylosis Treatment  Comprehensive Study by Type (Physical Therapy, Medications, Surgery Therapy), Application (Youth, Elderly) Players and Region - Global Market Outlook to 2026
$ 3500